Marrone Bio Innovations, Inc. (NASDAQ:MBII) Given Average Rating of “Buy” by Analysts

Shares of Marrone Bio Innovations, Inc. (NASDAQ:MBIIGet Rating) have been assigned an average recommendation of “Buy” from the six analysts that are currently covering the stock, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $2.08.

Several research analysts have weighed in on the company. Zacks Investment Research upgraded Marrone Bio Innovations from a “sell” rating to a “hold” rating in a research note on Friday, March 18th. StockNews.com assumed coverage on Marrone Bio Innovations in a research note on Sunday, April 3rd. They issued a “hold” rating for the company. Finally, Canaccord Genuity Group downgraded Marrone Bio Innovations from a “buy” rating to a “hold” rating and dropped their price target for the stock from $2.00 to $1.30 in a research note on Friday, March 18th.

In other news, Director Pamela G. Marrone sold 22,728 shares of the stock in a transaction that occurred on Thursday, March 24th. The stock was sold at an average price of $1.11, for a total transaction of $25,228.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 5.00% of the stock is currently owned by corporate insiders.

A number of large investors have recently added to or reduced their stakes in MBII. SG Americas Securities LLC purchased a new stake in Marrone Bio Innovations during the 3rd quarter valued at $31,000. Philadelphia Trust Co. purchased a new stake in Marrone Bio Innovations during the 4th quarter valued at $39,000. Allspring Global Investments Holdings LLC purchased a new stake in Marrone Bio Innovations during the 1st quarter valued at $43,000. Wells Fargo & Company MN raised its holdings in Marrone Bio Innovations by 676.8% during the 4th quarter. Wells Fargo & Company MN now owns 60,982 shares of the basic materials company’s stock valued at $44,000 after buying an additional 53,132 shares during the period. Finally, Clear Harbor Asset Management LLC raised its holdings in Marrone Bio Innovations by 41.1% during the 4th quarter. Clear Harbor Asset Management LLC now owns 75,677 shares of the basic materials company’s stock valued at $55,000 after buying an additional 22,027 shares during the period. Institutional investors own 68.42% of the company’s stock.

Shares of NASDAQ:MBII opened at $1.11 on Thursday. Marrone Bio Innovations has a 12-month low of $0.55 and a 12-month high of $1.95. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.26. The company has a market cap of $202.32 million, a PE ratio of -11.10 and a beta of 0.36. The stock has a 50 day moving average of $0.93 and a 200 day moving average of $0.81.

Marrone Bio Innovations (NASDAQ:MBIIGet Rating) last posted its quarterly earnings results on Monday, March 28th. The basic materials company reported ($0.03) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.03). Marrone Bio Innovations had a negative return on equity of 50.77% and a negative net margin of 37.35%. The business had revenue of $10.80 million during the quarter, compared to the consensus estimate of $10.40 million. During the same period in the prior year, the company posted ($0.03) EPS. Equities research analysts predict that Marrone Bio Innovations will post -0.05 earnings per share for the current fiscal year.

About Marrone Bio Innovations (Get Rating)

Marrone Bio Innovations, Inc discovers, develops, and sells biological products for crop protection, crop health, and crop nutrition. Its products include Emergen, Foramin, Foramin ST, Optima, Takla, Pacesetter, Ympact, UBP, and UBP ST for increasing crop health, yield, and quality; Grandevo, a bioinsecticide that controls sucking and chewing insects through feeding; Haven, a plant health product to reduce sun stress and dehydration; Jet-Ag and Jet-Oxide peroxyacetic acid sanitizers that prevent, suppress, eliminate, and control algae, fungi, and bacterial diseases in agriculture and horticultural industries; and Majestene, a bionematicide to control soil-dwelling nematodes and certain soil borne insects.

Further Reading

Receive News & Ratings for Marrone Bio Innovations Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marrone Bio Innovations and related companies with MarketBeat.com's FREE daily email newsletter.